Table 1

Baseline Characteristics

All (N = 98,846)ICD (n = 87,914)Control (n = 10,932)Standardized Difference
Age, yrs65.4 ± 12.165.6 ± 12.163.8 ± 11.70.151
Female23,626 (23.9)21,276 (24.2)2350 (21.5)0.064
NYHA functional class
 I8,332 (8.4)8,231 (9.4)101 (0.9)0.392
 II58,410 (59.1)52,557 (59.8)5,853 (53.5)0.127
 III32,104 (32.5)27,126 (30.9)4,978 (45.5)−0.304
Ischemic CM69,221 (70.0)63,059 (72.2)5712 (52.3)−0.419
Lung disease18,702 (18.9)17,792 (20.2)910 (8.3)0.345
Diabetes mellitus34,298 (34.7)31,587 (35.9)2,711 (24.8)0.243
LVEF25.8 ± 6.125.8 ± 6.125.2 ± 6.10.098
Creatinine, mg/dl1.19 ± 0.401.18 ± 0.401.25 ± 0.38−0.179
Sodium, mEq/l139.1 ± 3.1139.0 ± 3.1139.5 ± 3.3−0.156
Systolic BP, mm Hg130.6 ± 21.7131.4 ± 21.8123.5 ± 19.10.385
QRS, ms110.6 ± 23.5110.3 ± 24.6112.9 ± 11.7−0.135
Medications
 ACEI or ARB82,453 (83.4)71,936 (81.8)10,517 (96.2)−0.473
 Beta-blocker84,584 (85.6)78,162 (88.9)6,422 (58.7)0.731
 Digoxin25,971 (26.3)19,589 (22.3)6,382 (58.4)−0.791
 Diuretic64,029 (64.8)54,473 (62.0)9,556 (87.4)−0.611

Values in the middle columns are mean ± standard deviation or n (%). The standardized difference between groups for each parameter is shown in the last column.

ACEI = angiotensin-converting enzyme inhibitor; ARB = angiotensin receptor blocker; BP = blood pressure; CM = cardiomyopathy; LVEF = left ventricular ejection fraction; NYHA = New York Heart Association.